AJP - Endocrinology and Metabolism, Vol 265, Issue 4 E655-E659, Copyright © 1993 by American Physiological Society

ARTICLES

Circulating insulin levels are related to bone density in normal postmenopausal women

I. R. Reid, M. C. Evans, G. J. Cooper, R. W. Ames and J. Stapleton
Department of Medicine, University of Auckland, New Zealand.

We recently established that the dependence of bone mineral density (BMD) on body weight in women is mainly attributable to a close relationship between total body fat mass and BMD. The present study assesses whether this latter relationship might be contributed to by the hormones insulin or amylin, both of which may influence fat mass and calcium metabolism. Fifty-three normal postmenopausal women underwent a 75-g glucose tolerance test with measurement of plasma insulin and amylin concentrations every 30 min for 2 h. Body composition and BMD/height (to provide a quantity with the dimensions of volumetric density that is independent of body size) were measured by dual-energy X-ray absorptiometry, and volumetric density of the third lumbar vertebral body was calculated. Circulating insulin concentrations correlated with BMD/height and volumetric density of the third lumbar vertebral body (r = 0.28-0.52). They also were related to body weight (r = 0.34-0.56) and fat mass (r = 0.38-0.56) but were not independently related to lean mass on multiple regression. There were no consistent relationships between amylin levels and these variables. Multiple-regression analyses with fat mass and insulin levels as independent variables indicated that BMD/height of total body and femoral trochanter were primarily related to fat mass, whereas, in femoral neck, the significant relationship was with insulin. Volumetric density of the third lumbar vertebral body was related to insulin levels alone on this analysis.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				K. M. Thrailkill, C. K. Lumpkin Jr., R. C. Bunn, S. F. Kemp, and J. L. Fowlkes Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues Am J Physiol Endocrinol Metab, November 1, 2005; 289(5): E735 - E745. [Abstract] [Full Text] [PDF]

				J. Cornish, K. E. Callon, K. G. Mountjoy, U. Bava, J.-M. Lin, D. E. Myers, D. Naot, and I. R. Reid alpha -Melanocyte-stimulating hormone is a novel regulator of bone Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1181 - E1190. [Abstract] [Full Text] [PDF]

				T. A. DRAKE, E. SCHADT, K. HANNANI, J. M. KABO, K. KRASS, V. COLINAYO, L. E. GREASER III, J. GOLDIN, and A. J. LUSIS Genetic loci determining bone density in mice with diet-induced atherosclerosis Physiol Genomics, April 27, 2001; 5(4): 205 - 215. [Abstract] [Full Text] [PDF]

				J. A. Eisman Pharmacogenetics of the Vitamin D Receptor and Osteoporosis Drug Metab. Dispos., April 1, 2001; 29(4): 505 - 512. [Abstract] [Full Text]

				J. Cornish, K. E. Callon, C. Q.-X. Lin, C. L. Xiao, T. B. Mulvey, D. H. Coy, G. J. S. Cooper, and I. R. Reid Dissociation of the effects of amylin on osteoblast proliferation and bone resorption Am J Physiol Endocrinol Metab, May 1, 1998; 274(5): E827 - E833. [Abstract] [Full Text] [PDF]